Dr Harry Kovelman Joins Ferring Pharmaceuticals
This article was originally published in Scrip
Ferring Pharmaceuticals (US) has named Dr Harry Kovelman associate medical director for orthopaedics. He will be responsible for medical affairs for Euflexxa (1% sodium hyaluronate), a treatment for knee pain due to osteoarthritis, as well as Ferring's line of orthopaedic products. Dr Kovelman was previously director of medical affairs at Otto Bock HealthCare. He has also served as chief executive officer of Archimedes Medical Technology; executive director of the orthopaedic institute of St Joseph Medical Center; and medical affairs director and vice-president of sales and marketing at Dynasplint Systems.